European Journal of Nuclear Medicine and Molecular Imaging

, Volume 38, Issue 3, pp 515–525

Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography

Authors

    • Department of Nuclear MedicineUniversity of Leipzig
  • Henrike Wolf
    • Department of PsychiatryUniversity of Leipzig
    • Department of Old Age Psychiatry and Psychiatry Research, Psychiatric University Hospital (PUK) ZurichUniversity of Zurich
  • Philipp Mael Meyer
    • Department of Nuclear MedicineUniversity of Leipzig
  • Henryk Barthel
    • Department of Nuclear MedicineUniversity of Leipzig
  • Swen Hesse
    • Department of Nuclear MedicineUniversity of Leipzig
  • Georg Alexander Becker
    • Department of Nuclear MedicineUniversity of Leipzig
  • Julia Luthardt
    • Department of Nuclear MedicineUniversity of Leipzig
  • Andreas Schildan
    • Department of Nuclear MedicineUniversity of Leipzig
  • Marianne Patt
    • Department of Nuclear MedicineUniversity of Leipzig
  • Dietlind Sorger
    • Department of Nuclear MedicineUniversity of Leipzig
  • Anita Seese
    • Department of Nuclear MedicineUniversity of Leipzig
  • Herman-Josef Gertz
    • Department of PsychiatryUniversity of Leipzig
  • Osama Sabri
    • Department of Nuclear MedicineUniversity of Leipzig
Original Article

DOI: 10.1007/s00259-010-1644-5

Cite this article as:
Kendziorra, K., Wolf, H., Meyer, P.M. et al. Eur J Nucl Med Mol Imaging (2011) 38: 515. doi:10.1007/s00259-010-1644-5

Abstract

Purpose

Postmortem studies indicate a loss of nicotinic acetylcholine receptor (nAChRs) in Alzheimer’s disease (AD). In order to establish whether these changes in the cholinergic system occur at an early stage of AD, we carried out positron emission tomography (PET) with a specific radioligand for the α4β2* nicotinic acetylcholine receptor (α4β2* nAChR) in patients with mild to moderate AD and in patients with amnestic mild cognitive impairment (MCI), who have a high risk to progress to AD.

Methods

Nine patients with moderate AD, eight patients with MCI and seven age-matched healthy controls underwent 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[18F]FA-85380) PET. After coregistration with individual magnetic resonance imaging the binding potential (BPND) of 2-[18F]FA-85380 was calculated using either the corpus callosum or the cerebellum as reference regions. PET data were analysed by region of interest analysis and by voxel-based analysis.

Results

Both patients with AD and MCI showed a significant reduction in 2-[18F]FA-85380 BPND in typical AD-affected brain regions. Thereby, the corpus callosum was identified as the most suitable reference region. The 2-[18F]FA-85380 BPND correlated with the severity of cognitive impairment. Only MCI patients that converted to AD in the later course (n = 5) had a reduction in 2-[18F]FA-85380 BPND.

Conclusion

2-[18F]FA-85380 PET appears to be a sensitive and feasible tool for the detection of a reduction in α4β2* nAChRs which seems to be an early event in AD. In addition, 2-[18F]FA-85380 PET might give prognostic information about a conversion from MCI to AD.

Keywords

Nicotinic acetylcholine receptors2-[18F]FA-85380Alzheimer’s diseaseMCIPET

Copyright information

© Springer-Verlag 2010